P1-085: Utilization and effectiveness of Elbasvir/Grazoprevir (EBR/GZR) in treatment Naïve (TN) genotype 1a (G1a) chronic hepatitis C virus (HCV) patients with/without baseline NS5A resistance-associated substitutions (RASs)

2018 ◽  
Vol 25 ◽  
pp. 66-66
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Genotype 1A ◽  
Chronic Hepatitis C Virus ◽  
Treatment Naïve

scholarly journals NS3 Variability in Hepatitis C Virus Genotype 1A Isolates from Liver Tissue and Serum Samples of Treatment-Naïve Patients with Chronic Hepatitis C

Intervirology ◽  
2018 ◽  
Vol 61 (1) ◽  
pp. 1-8
Author(s):  
Deborah D’Aliberti ◽  
Irene Cacciola ◽  
Cristina Musolino ◽  
Giuseppina Raffa ◽  
Roberto Filomia ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Liver Tissue ◽  
Serum Samples ◽  
Virus Genotype ◽  
Genotype 1A ◽  
Treatment Naïve

scholarly journals Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment

2020 ◽  
Vol 26 (4) ◽  
pp. 554-561
Author(s):  
Desmond Y. H. Yap ◽  
Kevin S. H. Liu ◽  
Yu-Chun Hsu ◽  
Grace L. H. Wong ◽  
Ming-Chang Tsai ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Renal Impairment ◽  
Chronic Hepatitis C ◽  
Severe Renal Impairment ◽  
Asian Patients ◽  
Chronic Hepatitis C Virus ◽  
Treatment Naïve ◽  
Lost To Follow Up

Background/Aims: Data on treatment efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) for chronic hepatitis C virus (HCV) infection in Asian patients with severe renal impairment are limited. This study aimed to study the treatment and side effects of GLE/PIB in these patients infected with non-1 genotype (GT) HCV.Methods: We prospectively recruited patients with Child’s A cirrhosis and eGFR <30 mL/min/1.73 m<sup>2</sup> in Hong Kong and Taiwan during 2017–2018 to receive GLE/PIB treatment.Results: Twenty-one patients (GT2, n=7; GT3, n=6; and GT6, n=8) received GLE/PIB for 11.2±1.8 weeks. All except one were treatment-naïve. GLE/PIB was initiated in 16 patients while on dialysis (seven on peritoneal dialysis [PD] and nine on hemodialysis) and in five patients before dialysis. One patient died of PD-related peritonitis during treatment and two were lost to follow up. The SVR12 rate in the remaining 18 patients was 100%. All patients achieved undetectable levels at 4-, 12-, 24- and 48-week after treatment. Patients with deranged alanine aminotransferase showed normalization after 4 weeks and the response was sustained for 48 weeks. No significant adverse event was observed.Conclusions: GLE/PIB treatment was associated with high efficacy and tolerability in HCV-infected patients with severe renal impairment.

Sign in / Sign up

Export Citation Format

Share Document